Quantcast
Home > Quotes > ACOR
ACOR

Acorda Therapeutics, Inc. Common Stock (ACOR) Quote & Summary Data

$18.36
*  
0.94
4.87%
Get ACOR Alerts
*Delayed - data as of Nov. 14, 2018 14:35 ET  -  Find a broker to begin trading ACOR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ACOR Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 18.32 / $ 18.38
1 Year Target
21
Today's High / Low
$ 19.53 / $ 18.27
Share Volume
236,113
50 Day Avg. Daily Volume
967,945
Previous Close
$ 19.30
52 Week High / Low
$ 36.35 / $ 15.60
Market Cap
873,171,104
P/E Ratio
NE
Forward P/E (1y)
230
Earnings Per Share (EPS)
$ -3.19
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
236,113
50 Day Avg. Daily Volume:
967,945

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
230
Earnings Per Share (EPS):
$ -3.19

Trading Range

The current last sale of $18.36 is 17.69% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.53 $ 36.35
 Low: $ 18.27 $ 15.60

ETFs with ACOR as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0% Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) -1.63 (-5.41%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. We market two U.S. Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10mg, a treatment to improve walking in adult patients with multiple sclerosis, or MS, as demonstrated by an increase in walking speed. Ampyra 2017 net revenue was $543 million, an increase of approximately 10% over 2016. We have a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and MS. We currently derive substantially all our revenue from the sale of Ampyra.  ... More ...  


Risk Grade

Where does ACOR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 19.47
Open Date:
Nov. 14, 2018
Close Price:
$ 19.30
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x